Pharmaceutical Executive, May 2017 Issue (PDF)

Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.

When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

Prescription data between 2017 and 2023 revealed that while Adderall prescription fills decreased following the shortage, many children transitioned to alternative stimulants for attention-deficit/hyperactivity disorder.

The latest news for pharma industry insiders.